Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus erlotinib versus placebo plus erlotinib in MET-positive previously treated NSCLC
2011-002224-40Phase 3Completed
- Sponsor
- Genentech
- Start
- Jan 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Onartuzumab + Tarceva with Placebo + Tarceva (2 arms). Primary endpoint: Overall survival. Started Jan 2012; status: completed.
02
Drugs
onartuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-002224-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002224-40.